Chemotherapy can cause gout, though it does so indirectly by driving up levels of uric acid in the blood. When cancer treatment kills large numbers of cells rapidly, those cells release their internal contents, including purines that the body converts to uric acid. If uric acid climbs high enough and stays there, crystals can form in joints and trigger the searing pain of a gout flare. The connection is well established in oncology, but managing gout during active cancer treatment comes with complications that make it different from managing gout in someone who is otherwise healthy.
How Chemotherapy Drives Up Uric Acid
The central mechanism is cell death on a massive scale. Chemotherapy drugs are designed to destroy tumor cells, and many healthy cells get caught in the crossfire. As those cells break apart, they dump purines into the bloodstream. Your body metabolizes purines into uric acid, which the kidneys are supposed to filter out. But when cell destruction happens faster than the kidneys can keep up, uric acid accumulates.
In its most extreme form, this process is called tumor lysis syndrome. It tends to strike in cancers with a high tumor burden or rapidly dividing cells, particularly blood cancers like leukemia and aggressive lymphomas. Tumor lysis syndrome brings not just hyperuricemia but dangerous shifts in potassium, phosphorus, and calcium. The uric acid component, though, is the one most directly linked to gout: crystals can precipitate in joints, in kidney tubules, or both.
Even when tumor lysis syndrome doesn’t fully develop, chemotherapy can still push uric acid above the threshold where crystals begin to form. Some chemotherapy drugs also damage the kidneys directly, reducing their ability to excrete uric acid. This adds a second pathway to the same problem. A patient who had borderline-high uric acid before treatment might cross into gout territory once chemotherapy impairs kidney function.
Which Cancer Treatments Are Most Likely to Trigger Gout
Not all chemotherapy carries equal risk. The biggest concern has traditionally been with regimens used for hematologic cancers, where tumor lysis syndrome is most common. Drugs used for leukemias and high-grade lymphomas are the classic culprits, precisely because they kill so many cells so quickly.
Among solid-tumor chemotherapies, carboplatin has been linked to hyperuricemia through its potential to damage the kidneys, which impairs uric acid excretion. The fluoropyrimidine 5-fluorouracil (5-FU) has also been associated with elevated uric acid and kidney changes in preclinical studies.1PubMed Central. Acute Gout Flare After Carboplatin/5‐Fluorouracil for Locally Advanced Head and Neck Squamous Cell Carcinoma Gout flares from solid-tumor regimens are less frequently reported in the literature, but they do happen, especially in patients who already have risk factors like obesity, kidney disease, or a personal history of gout.
A newer category of concern is immune checkpoint inhibitors, which work very differently from traditional chemotherapy. These drugs unleash the immune system to fight cancer, but that same immune activation can trigger inflammatory conditions. Crystal arthropathies, including both gout and pseudogout, have been reported after checkpoint inhibitor therapy. One center documented cases of gout arising in patients on these drugs, noting that although tumor lysis syndrome and hyperuricemia had been observed with checkpoint inhibitors, gout specifically had gone largely unreported until recently.2Arthritis & Rheumatology. Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors Separately, recurrent pseudogout flares have been documented in a patient receiving nivolumab for renal cell carcinoma, with flares occurring roughly a week to ten days after each infusion.3PubMed Central. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
Telling Gout Apart from Other Joint Problems During Treatment
A swollen, painful joint during cancer treatment does not automatically mean gout. Cancer patients are vulnerable to several kinds of joint inflammation that can look almost identical on the surface. Septic arthritis, where bacteria infect the joint, is a serious risk in immunocompromised patients. Pseudogout, caused by calcium pyrophosphate crystals rather than uric acid crystals, can mimic gout so closely that you can’t tell them apart without testing the fluid inside the joint. Reactive arthritis, triggered by infection elsewhere in the body, is another possibility.
The single most reliable way to distinguish these conditions is synovial fluid analysis, where a doctor draws fluid from the affected joint and examines it under a microscope. Research comparing these types of arthritis in cancer patients has found that synovial fluid analysis distinguishes the causes far more accurately than blood tests alone.4Infectious Diseases in Clinical Practice. Contrasting the Clinical Presentation and Prevalence of Septic, Reactive, and Crystal Arthritis in Patients With Hematologic and Solid Malignancies This matters because the treatments are very different: antibiotics for infection, anti-inflammatory drugs for crystals. Getting the diagnosis wrong could mean missing a life-threatening infection or unnecessarily delaying cancer treatment.
One case involving a patient on T-cell receptor therapy who developed pseudogout illustrates an additional wrinkle: that patient’s joint inflammation resolved with tocilizumab, a drug given to treat cytokine release syndrome, a known side effect of some immunotherapies.5Journal for ImmunoTherapy of Cancer. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab The takeaway is that in the oncology setting, joint inflammation can have unusual causes and respond to unexpected treatments. If you develop sudden joint pain during cancer therapy, getting the joint tapped and analyzed is worth the discomfort of the procedure.
Managing an Acute Gout Flare During Chemotherapy
When a gout flare hits, the immediate goal is pain control and reducing inflammation. In the general population, the go-to drugs are NSAIDs like indomethacin or naproxen, colchicine, or corticosteroids. Evidence from a Cochrane review found that NSAIDs were more effective than placebo at reducing gout pain within 24 hours, though they increased gastrointestinal side effects.6Cochrane Database of Systematic Reviews. Non‐steroidal anti‐inflammatory drugs for acute gout
In cancer patients, each of these options carries additional baggage. NSAIDs can be risky for patients whose kidneys are already strained by chemotherapy, and they interfere with platelet function, which is a problem when chemotherapy has driven platelet counts down. Colchicine interacts with several drugs commonly used in cancer care and can worsen diarrhea, a frequent chemotherapy side effect. Corticosteroids are often the most practical choice because they are effective, don’t harm the kidneys, and don’t affect platelet function, but they come with their own downsides in cancer patients, including blood sugar spikes and potential immunosuppression layered on top of already suppressed immunity.
For patients who can’t tolerate any of the standard options, anakinra, an injectable drug that blocks an inflammatory protein called interleukin-1, has been used for refractory gout. In a series of ten patients with difficult-to-treat gout, six responded well, three had partial responses, and one didn’t respond. However, nine of the ten had recurrent flares after stopping the drug, anywhere from three to 45 days later.7PubMed. Anakinra’s efficacy is variable in refractory gout: report of ten cases Anakinra is not a first-line treatment, but it can be a useful option when the usual medications are off the table.
Drug Interactions Between Gout Medications and Chemotherapy
This is where managing gout during cancer treatment gets genuinely tricky, and where the stakes are highest. The most important interaction involves allopurinol, the drug most commonly used to lower uric acid levels, and 6-mercaptopurine, a chemotherapy drug used in leukemia treatment. Allopurinol works by blocking an enzyme called xanthine oxidase. That same enzyme is responsible for breaking down 6-mercaptopurine after it’s taken by mouth. When allopurinol blocks it, blood levels of 6-mercaptopurine can jump four- to five-fold, creating a serious risk of toxicity.8PubMed. Pharmacokinetic drug interactions of commonly used anticancer drugs9PubMed. Antineoplastic agents. Drug interactions of clinical significance
Oncologists are well aware of this interaction and will reduce the mercaptopurine dose accordingly or choose a different uric acid-lowering strategy altogether. But it illustrates a broader principle: gout management cannot happen in isolation from cancer treatment. Any medication added during chemotherapy needs to be vetted against the full drug regimen. This is one reason why your oncology team, rather than a primary care physician working independently, should ideally be coordinating gout treatment during active chemotherapy.
Febuxostat, a newer xanthine oxidase inhibitor, has also been studied in the cancer setting. In patients at risk for tumor lysis syndrome, febuxostat at a low dose was started before chemotherapy and continued through the first week of treatment to keep uric acid in check.10PubMed Central. Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome Like allopurinol, febuxostat blocks the same enzyme, so the same caution applies with mercaptopurine and related drugs. The advantage of febuxostat is that it doesn’t need dose adjustment for mild to moderate kidney impairment, which matters for cancer patients whose kidneys may already be stressed.
Preventing Uric Acid Buildup Before It Becomes Gout
Prevention is the preferred strategy, especially for patients at high risk of tumor lysis syndrome. The standard approach combines aggressive intravenous hydration to keep urine flowing, urinary alkalinization to make uric acid more soluble, and a xanthine oxidase inhibitor like allopurinol to slow uric acid production.11PubMed. Renal and metabolic toxicities of cancer chemotherapy These measures are started before chemotherapy begins, not after uric acid has already spiked.
For patients at the highest risk, such as those with large, rapidly growing tumors or very high baseline uric acid levels, rasburicase offers a more aggressive option. Rasburicase is an enzyme that directly breaks down uric acid into a more soluble compound that the kidneys can easily clear. A systematic review of over 1,200 adult patients found that rasburicase was effective at normalizing uric acid in about 93% of patients receiving it.12American Journal of Kidney Diseases. Efficacy and Safety of Rasburicase in Adults at Risk for Tumor Lysis Syndrome: A Systematic Review and Meta-Analysis However, the same review noted that evidence was lacking on whether rasburicase actually improved clinical outcomes like kidney failure or death compared to other approaches. Additionally, rasburicase is expensive. The review concluded that its use might be best reserved for high-risk patients until better comparative data becomes available.12American Journal of Kidney Diseases. Efficacy and Safety of Rasburicase in Adults at Risk for Tumor Lysis Syndrome: A Systematic Review and Meta-Analysis
For patients with a personal history of gout who are about to begin chemotherapy, having a conversation with the oncology team beforehand is critical. If you’ve had gout flares in the past, your baseline uric acid may already be elevated, meaning the additional burden of cell breakdown during chemotherapy could push you into a flare far more easily than it would someone starting from a lower baseline. Preventive uric acid-lowering therapy may need to be initiated or adjusted before the first chemotherapy cycle.
Diet and Lifestyle Adjustments During Cancer Treatment
Diet is a secondary lever compared to medications, but it can make a meaningful difference, especially for patients who experience mild hyperuricemia that doesn’t quite reach the level requiring aggressive drug therapy. Research on dietary modification in cancer patients has found that carefully designed plant-based dietary plans can reduce the risk of gout flares while still meeting the elevated protein and micronutrient needs that come with cancer treatment.13PubMed. Dietary modulation of purine metabolism and uric acid homeostasis in cancer patients with an ileostomy Plant-derived bioactive compounds may also help reduce the inflammation and oxidative stress that accompany both cancer and hyperuricemia.
The challenge is that dietary advice for gout, which typically means limiting red meat, organ meats, shellfish, and alcohol, can conflict with the nutritional demands of cancer treatment. Cancer patients often struggle with appetite, nausea, and weight loss, and being told to further restrict their diet can feel impossible. The practical approach is to focus on the highest-impact substitutions rather than sweeping restrictions:
- Hydration: Drinking plenty of fluids helps the kidneys excrete uric acid. This is the simplest and most universally applicable recommendation.
- Protein sources: Swapping red meat and shellfish for eggs, dairy, and plant-based proteins like lentils and tofu reduces purine intake without sacrificing protein.
- Alcohol: Beer is particularly high in purines, and alcohol in general impairs uric acid excretion. Most oncologists already advise minimizing alcohol during treatment.
- Cherries and vitamin C: Both have modest evidence for lowering uric acid in the general population and are unlikely to cause harm during cancer treatment.
Nutrition counseling before and during chemotherapy can help patients avoid hyperuricemia and potentially prevent the need for hospitalization or expensive uric acid-lowering drugs.14Journal of the American Society of Nephrology. Dietary Hyperuricemia Causes Nephropathy in a Cancer Patient If your cancer center has a registered dietitian, involving them early is worthwhile.
Who Is at Highest Risk
Several factors stack the odds in favor of a gout flare during chemotherapy. Pre-existing hyperuricemia or a previous gout diagnosis is the most obvious one. Beyond that, the type of cancer matters: hematologic malignancies with a high tumor burden carry the greatest risk because of the sheer volume of cell death during treatment. Kidney impairment, whether pre-existing or caused by chemotherapy, reduces the body’s ability to clear uric acid. Dehydration from nausea and vomiting, common during chemotherapy, further concentrates uric acid in the blood. Certain medications frequently given alongside chemotherapy, such as diuretics, can also raise uric acid.
Age compounds the picture. Older patients are more likely to have pre-existing gout, more likely to have reduced kidney function, and more likely to be on medications that affect uric acid. Men are at higher risk than women for gout in general, and this disparity persists in the cancer setting. If you check multiple boxes on this list, it’s worth asking your oncologist specifically about uric acid monitoring during treatment, even if gout hasn’t come up in conversation.
The Quality-of-Life Burden of Gout Flares
It’s easy to dismiss gout as a minor annoyance in the context of cancer treatment, but a gout flare during chemotherapy can be genuinely debilitating. A large cross-sectional study of gout patients found that those experiencing an active flare had dramatically lower quality-of-life scores compared to those not in a flare, with health utility scores dropping from about 0.89 to 0.34 and self-rated health scores falling from roughly 84 to 55 on a 100-point scale.15PubMed. Impact of gout flare on health-related quality of life: a multi-center cross-sectional study in Thailand Those numbers represent a severe hit to daily functioning, and that’s in patients who aren’t simultaneously dealing with chemotherapy side effects, cancer-related fatigue, and the psychological weight of a cancer diagnosis.
When gout strikes during chemotherapy, it can also disrupt the treatment schedule itself. Severe pain may make it impossible to get to infusion appointments. Joint swelling in the hands can interfere with daily tasks that are already harder during treatment. In some cases, the medications needed to treat the gout flare interact with chemotherapy drugs, forcing dose adjustments or delays. Any interruption in a chemotherapy schedule has the potential to affect outcomes, so preventing gout flares isn’t just about comfort: it’s about keeping cancer treatment on track.
When Gout Persists After Chemotherapy Ends
Some patients find that the gout triggered by chemotherapy doesn’t simply go away when treatment is finished. If uric acid stayed elevated long enough during treatment, crystals may have deposited in joints and soft tissues, creating a reservoir that can provoke flares for months or years. Kidney damage sustained during chemotherapy can permanently reduce uric acid clearance, leaving the patient with a chronic gout risk that didn’t exist before their cancer diagnosis.
For these patients, long-term uric acid-lowering therapy becomes a serious consideration. Febuxostat and allopurinol are the mainstays, with the choice between them depending on kidney function, other medications, and individual tolerance. Target uric acid levels for preventing recurrent gout are generally below 6 mg/dL, and often below 5 mg/dL for patients with established crystal deposits. Cancer survivors who developed gout during treatment should have their uric acid monitored during follow-up visits, ideally by someone who understands both the rheumatologic and oncologic context. The last thing a cancer survivor needs is a preventable chronic pain condition layered on top of their recovery.